DrugPatentWatch Database Preview
RAPAFLO Drug Profile
» See Plans and Pricing
When do Rapaflo patents expire, and when can generic versions of Rapaflo launch?
Rapaflo is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in RAPAFLO is silodosin. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the silodosin profile page.
US ANDA Litigation and Generic Entry Outlook for Rapaflo
A generic version of RAPAFLO was approved as silodosin by SANDOZ INC on March 31st, 2017.
Summary for RAPAFLO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 76 |
| Clinical Trials: | 7 |
| Patent Applications: | 357 |
| Drug Prices: | Drug price information for RAPAFLO |
| DailyMed Link: | RAPAFLO at DailyMed |
Recent Clinical Trials for RAPAFLO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sir Mortimer B. Davis - Jewish General Hospital | Phase 3 |
| Albert Einstein Healthcare Network | Phase 4 |
| Watson Pharmaceuticals | Phase 2 |
Pharmacology for RAPAFLO
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
US Patents and Regulatory Information for RAPAFLO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Allergan | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-002 | Oct 8, 2008 | AB | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RAPAFLO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-002 | Oct 8, 2008 | Start Trial | Start Trial |
| Allergan | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | Start Trial | Start Trial |
| Allergan | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | Start Trial | Start Trial |
| Allergan | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RAPAFLO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 0745185 | Start Trial |
| Australia | 1280195 | Start Trial |
| Israel | 110902 | Start Trial |
| World Intellectual Property Organization (WIPO) | 9507075 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for RAPAFLO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0600675 | SPC/GB10/031 | United Kingdom | Start Trial | PRODUCT NAME: SILODOSIN, OPTIONALLY IN A FORM OF A PHARMACEUTICAL ACCEPTABLE SALT; REGISTERED: UK EU/1/09/607/001-014 20100129; UK EU/1/09/608/001-014 20100129 |
| 0600675 | 1090028-0.L | Sweden | Start Trial | PRODUCT NAME: SILODOSIN ELLER FARMACEUTISKA GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/09/607/001-014 " EESGODKLANDKOD="EG" EESGODKDATUM="2010-01-29" SEGODKNR="EU/1/09/607/001-014 " SEGODKLANDKOD="EG" SEGODKDATUM="2010-01-29" FLAG="L" SPCNR="1090028-0" 20100129 |
| 0600675 | 10C0036 | France | Start Trial | PRODUCT NAME: SILODOSIN; REGISTRATION NO/DATE IN FRANCE: EU/1/09/608/001 DU 20100129; REGISTRATION NO/DATE AT EEC: EU/1/09/608/001 DU 20100129 |
| 0600675 | C300454 | Netherlands | Start Trial | PRODUCT NAME: SILODOSIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/09/607/001-014EU/1/09/608/001-014 2010290129 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
